BioNTech SE (BNTX)
About BioNTech SE
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $22.3B
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $22.3B
- Shares outstanding
- 249.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 10, 2019
BioNTech SE (BNTX) Stock Price
- Trading 25% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review BioNTech SE.
Write a review
News about BioNTech SE
News & sentiment via Polygon.io
BioNTech SE: frequently asked questions
Is BioNTech SE an American company?
BioNTech SE is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is BioNTech SE publicly traded?
Yes — BioNTech SE is a publicly traded company. Its stock trades under the ticker symbol BNTX on the NASDAQ.
What does BioNTech SE do?
BioNTech SE is an American Pharmaceuticals company in the Health & Beauty sector.
When was BioNTech SE founded?
BioNTech SE was founded in 2008.
